Market revenue in 2022 | USD 9.6 million |
Market revenue in 2030 | USD 21.1 million |
Growth rate | 10.3% (CAGR from 2022 to 2030) |
Largest segment | 13-24 weeks |
Fastest growing segment | 0-12 weeks |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | 0-12 weeks, 13-24 weeks, 25-36 weeks |
Key market players worldwide | CooperSurgical, Natera Inc, Eurofins Scientific SE, Illumina Inc, Centogene NV Ordinary Shares, MedGenome, Myriad Genetics Inc, Roche Holding AG, Qiagen NV, Labcorp Holdings Inc, Quest Diagnostics Inc, Biora Therapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non invasive prenatal testing market will help companies and investors design strategic landscapes.
13-24 weeks was the largest segment with a revenue share of 52.08% in 2022. Horizon Databook has segmented the Norway non invasive prenatal testing market based on 0-12 weeks, 13-24 weeks, 25-36 weeks covering the revenue growth of each sub-segment from 2018 to 2030.
Continuous developments by companies operating in the market are contributing to the country’s growth. In June 2020, NIPT was made permissible for all pregnant women in Norway, owing to changes in the Biotechnology Act passed by the Norwegian Parliament.
It further means that all pregnant women who want to know if their fetus does have certain chromosome abnormalities will shortly be able to do so in Norway rather than traveling to Sweden or Denmark, which many have done in earlier years. Thus, it will increase the demand for NIPTs and further fuel the market.
As sequencing is used more frequently in clinical settings in Norway, practical and ethical concerns are emerging around the creation of Informed Consent (IC) documents and their processes. To build a suitable IC process for testing in the clinical setting, it is difficult to bridge the gap between Norwegian legislation and regulations and clinical practice.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway non invasive prenatal testing market , including forecasts for subscribers. This country databook contains high-level insights into Norway non invasive prenatal testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account